Govt Jobs for Doctors, Nurses, Lab technicians under NHM

National Health Mission (NHM), Ratnagiri released a notification of 72 vacancies for Medical Officer & Other Posts.

NHM Ratnagiri Recruitment invited applications for Medical Officer & Other Posts through direct recruitment. Eligible candidates can apply for the post on or before 14th June 2021.

NHM Maharashtra has notified a total of 166 vacancies against the advertisement number. The candidates willing to apply for the posts can apply through online mode.

The applicants who are looking for Govt jobs in Maharashtra and are willing to apply for the above posts should have completed 10th, Graduation, B.Sc Nursing, MBBS, Post Graduation or equivalent from a recognized university.

The vacancies are available for Medical Officer & Other Posts.

NHM Ratnagiri Recruitment 2021 – 72 Vacancies

National Health Mission (NHM), Maharashtra released 72 vacancies for NHM Maharashtra Recruitment for Medical Officer & Other Posts. This is good news for candidates looking for Govt jobs in Maharashtra.

NHM Maharashtra Recruitment Notification is released on 1st June 2021. This is a good opportunity for candidates seeking Government Jobs for graduates.

The applicant must read the NHM Maharashtra Recruitment notification before applying to the above posts. Age Limit for these Medical Officer & Other posts is 42 years. Eligible and Interested Candidates can apply on or before 14th June 2021.

Name of the Post:

  • Medical Officer
  • Staff Nurse
  • Lab Technician & Other

No. of Vacancies: 72

Job Location: Maharashtra

Pay Scale: Not Mentioned

Eligibility Criteria: Applicants should have passed 12th, B.Sc, BAMS, GNM, Post Graduation or equivalent from a recognized university for NHM Maharashtra Recruitment 2021.

Age Limit:

  • Minimum Age Limit: 18
  • Maximum Age Limit: 70

Selection Process:

  • Written Test
  • Interview

How to Apply:
Eligible and interested applicants can apply online at the official website page at https://ratnagiri.gov.in/ NHM Maharashtra Recruitment 2021.

Important Dates:

  • Starting Date for Submission of Application: 01/06/2021
  • Last date for Submission of Application: 14/06/2021

Related Posts

Centre bans fixed-dose combination for Common Cold in children below four

The ministry said the use of “Chlorpheniramine Maleate and Phenylephrine Hydrochloride” drug combination in children below four years could pose health risks, while their safer alternatives are available in the…

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

A new peer-reviewed paper by neuroscientist Dale E. Bredesen proposes a unifying framework that could fundamentally change how researchers understand Alzheimer’s disease and other neurodegenerative disorders. Published on August 11…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Centre bans fixed-dose combination for Common Cold in children below four

Centre bans fixed-dose combination for Common Cold in children below four

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

New research study proposes a unifying theory for Alzheimer’s disease and other neurodegenerative diseases

Brain organoid maturation is driven by a lifelike developmental clock: Study

Brain organoid maturation is driven by a lifelike developmental clock: Study

Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

Delhi Police Bust ₹9-Crore Interstate Cancer Drug Diversion Network: 17 Arrested; 588 Anti-Cancer Vials, ₹50 Lakh Cash Seized

‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

‘Smart’ Cancer Drug RK-251 Developed by Indian Scientists Could Offer Targeted Alternative to Chemotherapy

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses